Evidence map›Paper›PMID 41052879›Full record

ArticleJournal for immunotherapy of cancer2025

Jingjing Wang, Yang Xie, Li Liu, Shuo Rong, Huanhuan Cai, Hao Zeng, Li Zhou, Keqiong Deng, Mengqiao Dai, Chao Xu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jingjing Wang *Longnan Hospital, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.ORCID http://orcid.org/0000-0002-6043-0964
Yang Xie *Longnan Hospital, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Li LiuLongnan Hospital, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Shuo RongState Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Taikang Center for Life and Medical Sciences, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
Huanhuan CaiDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China.
Hao ZengState Key Laboratory Breeding Base of Basic Science of Stomatology (HubeiMOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China.
Li ZhouState Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Taikang Center for Life and Medical Sciences, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
Keqiong DengDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China.
Mengqiao DaiLongnan Hospital, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Chao XuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Ying ZhuState Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Taikang Center for Life and Medical Sciences, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
Zhibing LuDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China.
Xuemin SongThe Research Centre of Anesthesiology and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xiangtai ZengLongnan Hospital, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China liushi_liushi@whu.edu.cn xiangtai.zeng@gmu.edu.cn.
Shi LiuLongnan Hospital, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China liushi_liushi@whu.edu.cn xiangtai.zeng@gmu.edu.cn.ORCID http://orcid.org/0000-0002-9289-0631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough some tumors respond to immune checkpoint blockade therapy, checkpoint inhibitors have been unsuccessful in treating uterine corpus endometrial cancer (UCEC), and the underlying molecular mechanisms remain unclear.

methodsWe investigated glucose flux regulation in UCEC cells with a focus on the hexosamine biosynthesis pathway (HBP). The role of

resultsWe found that UCEC cells direct glucose flux to the HBP. OGT, a critical enzyme for protein

conclusionsOur findings reveal cross-talk between the HBP, steroid hormone pathway, and tumor immune evasion, and suggest potential strategies for sensitizing UCEC to immunotherapy.

Indexed as

Drug Resistance, NeoplasmEndometrial NeoplasmsImmune EvasionImmunotherapyN-AcetylglucosaminyltransferasesReceptors, GlucocorticoidAnimalsCell Line, TumorFemaleHumansMiceN-AcetylglucosaminyltransferasesO-GlcNAc transferaseOGT protein, humanReceptors, GlucocorticoidImmune Checkpoint InhibitorImmune modulatoryImmunotherapyT cellTumor infiltrating lymphocyte - TIL

Identifiers

PMID41052879
PMCPMC12506452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.